Bortezomib 3.5 mg/1 (Bortezomib INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 3.5 mg/1

Bortezomib 3.5 mg/1 is a lyophilized powder for solution, used for intravenous or subcutaneous administration. It is commonly associated with certain cancer treatments. This product is manufactured by Hospira, Inc. in the USA.

Strength

3.5 mg/1

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (0409-1700-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in

Manufacturer / TM Owner

Hospira, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bortezomib 3.5 mg/1 is primarily used in the management of specific types of cancer. It works by interfering with the growth of cancer cells. Patients often wonder, 'What is Bortezomib used for?' and it is typically prescribed for conditions that require targeted therapy.

Side Effects

Common effects of Bortezomib may include fatigue, nausea, and peripheral neuropathy. Some users may experience gastrointestinal issues or changes in blood cell counts. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

Bortezomib should be handled with care, as it is a potent medication. It is important to follow proper storage and administration guidelines. Patients with pre-existing conditions should discuss their medical history with a healthcare professional before use.

Avoid Interactions

Bortezomib may interact with other medications, including those that affect the liver or blood cells. It is advisable to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also impact its effects.

References

Frequently Asked Questions

Bortezomib is commonly used in the treatment of certain types of cancer, particularly those that require targeted therapy.

Bortezomib is available as a lyophilized powder for solution, which can be administered intravenously or subcutaneously.

Common side effects may include fatigue, nausea, and peripheral neuropathy. Always consult a healthcare provider for detailed information.

Bortezomib may interact with other medications, so it is important to discuss all current medications with a healthcare provider.

Bortezomib should be stored according to the manufacturer's guidelines to maintain its efficacy and safety.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.